On the diagnosis and treatment of nosocomial tracheobronchitis in intensive care medicine
#2018-1
PDF_2018-1_43-47 (Русский)

Keywords

nosocomial pneumonia
nosocomial tracheobronchitis
sepsis
antibiotics
inhalation
colistin
tobramycin

How to Cite

Kuzovlev AN, Shabanov AK, Grechko AV On the diagnosis and treatment of nosocomial tracheobronchitis in intensive care medicine. Annals of Critical Care. 2018;(1):43–47. doi:10.21320/1818-474X-2018-1-43-47.

Statistic

Abstract Views: 2
PDF_2018-1_43-47 (Русский) Downloads: 0
Plum Analytics

Language

English Русский

Social Networks

Keywords

Up

Abstract

This review highlights the current state of the problem of nosocomial pneumonia and nosocomial tracheobronchitis. The important concept for nosocomial tracheobronchitis, the role of inhaled antibiotics in the treatment of this condition and their ability to prevent the development of nosocomial pneumonia are discussed.
https://doi.org/10.21320/1818-474X-2018-1-43-47
PDF_2018-1_43-47 (Русский)

References

  1. Гельфанд Б.Р. Нозокомиальная пневмония у взрослых. Российские национальные рекомендации. М.: МИА, 2016. [Gelfand B.R. Nozokomialʼnaya pnevmoniya u vzroslyh. Rossijskie nacionalʼnye rekomendacii. Moscow: МIА, 2016. (In Russ)]
  2. Susan E., Coffin M.M., Klompas M., et al. Strategies to prevent ventilator‐associated pneumonia in acute care hospitals. Infection Control and Hospital Epidemiology. 2008; 29: S31–40. doi: 10.1086/591062.
  3. КузовлевА.Н., Гречко А.В. Ингаляционные антибиотики в реаниматологии: состояние, проблемы и перспективы развития. Общая реаниматология. 2017, 13(5): 69–85. [Kuzovlev A.N., Grechko A.V. Ingalyacionnye antibiotiki v reanimatologii: sostoyanie, problemy i perspektivy razvitiya. Obshchaya reanimatologiya, 2017, 13(5): 69–85. (In Russ)]. doi: dx.doi.org/10.15360/1813-9779-2017-5-69-84.
  4. Imberti R., Cusato M., Villani P., et al. Steady-state pharmacokinetics and BAL concentration of colistin in critically ill patients after IV colistin methanesulfonate administration. Chest. 2010; 138:1333–1339. doi: 10.1378/chest.10-0463.
  5. Kollef M.H., Chastre J., Clavel M., et al. A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator- associated pneumonia. Crit. Care. 2012; 16(6): R218. doi: 10.1186/cc11862.
  6. Dulhunty J.M., Roberts J.A., Davis J.S., et al. A multicenter randomized trial of continuous versus intermittent beta-lactam infusion in severe sepsis. Am. J. Respir. Crit. Care Med. 2015; 192(11): 1298–1305. doi: 10.1164/rccm.201505–0857OC.
  7. Tamma P.D., Putcha N., Suh Y.D., et al. Does prolonged beta-lactam infusions improve clinical outcomes compared to intermittent infusions? A meta-analysis and systematic review of randomized, controlled trials. BMC Infect. Dis. 2011; 11: 181. doi: 10.1186/1471-2334-11-181.
  8. Marcus R., Paul M., Elphick H., et al. Clinical implications of beta-lactam-aminoglycoside synergism: systematic review of randomized trials. Int. J. Antimicrob. Agents. 2011; 37(6): 491–503. doi: 10.1016/j.ijantimicag.2010.11.029.
  9. Chastre J., Wolff M., Fagon J.Y., et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA. 2003; 290(19): 2588–2598.
  10. Wunderink R.G. POINT: Should Inhaled Antibiotic Therapy Be Used Routinely for the Treatment of Bacterial Lower Respiratory Tract Infections in the ICU Setting? Chest. 2017; 151(4): 737–739. doi: 10.1016/j.chest.2016.11.006.
  11. Niederman M.S., Chastre J., Corkery K., et al. BAY41–6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with gram-negative pneumonia. Intensive Care Med. 2012; 38(2): 263–271. doi: 10.1007/s00134-011-2420-0.
  12. Le J., Ashley E.D., Neuhauser M.M., et al. Consensus summary of aerosolized antimicrobial agents: application of guideline criteria. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2010; 30(6): 562–584. doi: 10.1592/phco.30.6.562.
  13. Weers J. Inhaled antimicrobial therapy — barriers to effective treatment. Adv. Drug. Deliv. Rev. 2015, 85: 24–43. doi: 10.1016/j.addr.2015.04.014.
  14. Lu Q., Yang J., Liu Z., et al. Nebulized Antibiotics Study Group. Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Am. J. Respir. Crit. Care Med. 2011; 184(1): 106–115. doi: 10.1164/rccm.201011–1894OC.
  15. Ferrari F., Lu Q., Girardi C., Petitjean O., et al. Nebulized ceftazidime in experimental pneumonia caused by partially resistant Pseudomonas aeruginosa. Intensive Care Med. 2009; 35:1792–1800. doi: 10.1007/s00134-009-1605-2.
  16. Lu Q., Girardi C., Zhang M., et al. Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa. Intensive Care Med. 2010; 36: 1147–1155. doi: 10.1007/s00134-010-1879-4.
  17. Alves J., Alp E., Koulenti D., et al. Nebulization of antimicrobial agents in mechanically ventilated adults in 2017: an international cross-sectional survey. Eur. J. Clin. Microbiol. Infect. Dis. 2018; 37(4): 785–794. doi: 10.1007/s10096-017-3175-5.
  18. Rello J., Solé-Lleonart C., Rouby J.J., et al. Use of Nebulized Antimicrobials for the Treatment of Respiratory Infections in Invasively Mechanically Ventilated Adults: A Position Paper from the European Society of Clinical Microbiology and Infectious Diseases. Clin. Microbiol. Infect. 2017; 23(9): 629–639. doi: 10.1016/j.cmi.2017.04.011.
  19. Kalil A., Metersky M., Klompas M., et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin. Infect. Dis. 2016; 63(5): 575–582. doi: 10.1093/cid/ciw504.
  20. А.Н.Кузовлев, А.К. Шабанов, А.М. Голубев, В.В. Мороз. Оценка эффективности ингаляционного колистина при нозокомиальной пневмонии. Общая реаниматология. 2017: 13(6): 60–74. [A.N. Kuzovlev, A.K. Shabanov, A.M. Golubev, V.V. Moroz. Ocenka ehffektivnosti ingalyacionnogo kolistina pri nozokomialʼnoj pnevmonii. Obshchaya reanimatologiya. 2017; 13(6): 60–74. (In Russ)] doi: dx.doi.org/10.15360/1813-9779-2017-6-60-73.
  21. КузовлевА.Н., Мороз В.В., Голубев А.М. Ингаляционные антибиотики в лечении нозокомиальной пневмонии. Анестезиология и реаниматология. 2015; 4: 68–74.
  22. Karvouniaris M., Makris D., Manoulakas E., et al. Ventilator-associated tracheobronchitis increases the length of intensive care unit stay. Infect. Control. Hosp. Epidemiol. 2013; 34(8): 800–808. doi: 10.1086/671274.
  23. Martin-Loeches I., Povoa P., Rodríguez A., et al. TAVeM study. Incidence and prognosis of ventilator-associated tracheobronchitis (TAVeM): a multicentre, prospective, observational study. Lancet Respir. Med. 2015; 3(11): 859–868. doi: 10.1016/S2213–2600(15)00326–4.
  24. Craven D.E., Lei Y., Ruthazer R., et al. Incidence and outcomes of ventilator-associated tracheobronchitis and pneumonia. Am. J. Med. 2013; 126: 542–549. doi: 10.1016/j.amjmed.2012.12.012.
  25. Nseir S., Deplanque X., Di Pompeo C., et al. A Risk factors for relapse of ventilator-associated pneumonia related to nonfermenting Gram negative bacilli: a case–control study. J. Infect. 2008; 56: 319–325. doi: 10.1016/j.jinf.2008.02.012.
  26. Luna C.M., Aruj P., Niederman M.S., et al. Appropriateness and delay to initiate therapy in ventilator-associated pneumonia. Eur. Respir. J. 2006, 27: 158–164.
  27. Palmer L.B., Smaldone G.C., Chen J.J., et al. Aerosolized antibiotics and ventilator-associated tracheobronchitis in the intensive care unit. Crit. Care Med. 2008, 36(7): 2008–2013. doi: 10.1097/CCM.0b013e31817c0f9e.
  28. Nseir S., Favory R., Jozefowicz E., et al. Antimicrobial treatment for ventilator-associated tracheobronchitis: a randomized, controlled, multicenter study. Crit. Care. 2008, 12(3): R62. doi: 10.1186/cc13940.
  29. Claridge J.A., Edwards N.M., Swanson J., et al. Aerosolized ceftazidime prophylaxis against ventilator-associated pneumonia in high-risk trauma patients: results of a double-blind randomized study. Surg. Infect. (Larchmt). 2007; 8(1): 83–90. doi: 10.1089/sur.2006.042.
  30. Karvouniaris M., Makris D., Zygoulis P., et al. Nebulized colistin for ventilator-associated pneumonia prevention. Eur. Respir. J. 2015; 46(6): 1732–1739. doi: 10.1183/13993003.02235–2014.
  31. Russell C.J., Shiroishi M.S., Siantz E., et al. The use of inhaled antibiotic therapy in the treatment of ventilator-associated pneumonia and tracheobronchitis: a systematic review. BMC Pulm. Med. 2016; 16: 40. doi: 10.1186/s12890-016-0202-8.
  32. Póvoa F.C.C., Cardinal-Fernandez P., Maia I.S., et al. Effect of antibiotics administered via the respiratory tract in the prevention of ventilator-associated pneumonia: A systematic review and meta-analysis. J.Crit. Care. 2018; 43: 240–245. doi: 10.1016/j.jcrc.2017.09.019.
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Copyright (c) 2018 ANNALS OF CRITICAL CARE

Downloads

Download data is not yet available.